<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01500317</url>
  </required_header>
  <id_info>
    <org_study_id>11-002334</org_study_id>
    <secondary_id>Pharmacodynamic study</secondary_id>
    <secondary_id>UL1RR024150</secondary_id>
    <nct_id>NCT01500317</nct_id>
  </id_info>
  <brief_title>Comparison of the Effects of Tapentadol and Oxycodone on Gastrointestinal and Colonic Transit in Humans</brief_title>
  <acronym>tap-oxy</acronym>
  <official_title>Comparison of the Effects of Tapentadol and Oxycodone on Gastrointestinal and Colonic Transit in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tapentadol is FDA approved for the treatment of moderate to severe acute pain. Due to the
      dual mechanism of action as an opioid agonist and norepinephrine reuptake inhibitor, there is
      potential for off label use in chronic pain.

      Tapentadol is a new molecular entity that is structurally similar to tramadol. Tapentadol is
      a centrally-acting analgesic with a dual mode of action as an agonist at the mu-opioid
      receptor and as a norepinephrine reuptake inhibitor. These two actions are synergistic in
      pain relief. While its action reflects aspects of tramadol and morphine, its ability to
      control pain is more on the order of hydrocodone and oxycodone.

      Its dual mode of action provides analgesia at similar levels of more potent narcotic
      analgesics such as hydrocodone, oxycodone, and meperidine with a more tolerable side effect
      profile. Clinical studies showed that tapentadol effectively relieves moderate to severe pain
      in various pain care settings. In addition, it was reported to be associated with
      significantly fewer treatment discontinuations due to a significantly lower incidence of
      gastrointestinal-related adverse events compared with equivalent doses of oxycodone. The
      combination of these reduced treatment discontinuation rates and tapentadol efficacy for the
      relief of moderate to severe nociceptive and neuropathic pain may offer an improvement in
      pain therapy by increasing patient compliance with their treatment regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single center, parallel group, randomized controlled trial of tapentadol, oxycodone and
      placebo effects on gastrointestinal and colonic transit in healthy human volunteers
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Colonic Transit, Geometric Center at 24 Hours</measure>
    <time_frame>24 hours</time_frame>
    <description>The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gastric Emptying Half-time (t1/2) at 24 Hours</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Colonic Geometric Center at 8 and 48 Hours</measure>
    <time_frame>8 hours, 48 hours</time_frame>
    <description>The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colonic Filling at 6 Hours</measure>
    <time_frame>6 hours</time_frame>
    <description>Percent of the radio-labeled meal that reached the colon at 6 hours, indirectly reflecting small bowel transit time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ascending Colon Emptying (AC t1/2)</measure>
    <time_frame>Over the first 24 hours after ingestion of the radioisotopically labeled charcoal particles</time_frame>
    <description>Ascending colon emptying t1/2 will be estimated by power exponential analysis of the proportionate emptying over time of counts from the colon. The primary data for this analysis will be the proportion of decay and depth-corrected counts in the ascending colon on the hourly scans on the first day of transit measurement and the 24 hour data.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Effects of 2 Mu-opiates on Gastrointestinal Transit</condition>
  <arm_group>
    <arm_group_label>Tapentadol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>75 mg tapentadol tid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxycodone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 mg oxycodone tid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tapentadol</intervention_name>
    <description>Subjects received tapentadol immediate release formulation, 75 mg three times per day (tid) for 48 hours.</description>
    <arm_group_label>Tapentadol</arm_group_label>
    <other_name>Tapentadol brand name: Nucynta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <description>Subjects received oxycodone immediate release formulation, 5 mg three times per day (tid) for 48 hours.</description>
    <arm_group_label>Oxycodone</arm_group_label>
    <other_name>Dazidox</other_name>
    <other_name>ETH-Oxydose</other_name>
    <other_name>Endocodone</other_name>
    <other_name>Oxecta</other_name>
    <other_name>Oxy IR</other_name>
    <other_name>Oxycontin</other_name>
    <other_name>Oxyfast</other_name>
    <other_name>Percolone</other_name>
    <other_name>Roxicodone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects received placebo three times per day (tid) for 48 hours.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Healthy volunteers Inclusion criteria

          1. Males and non-pregnant, non-breastfeeding females

          2. 18-65 years old

        Exclusion criteria

          1. Use of any mu-opioid agent in the last 3 months

          2. Structural or metabolic diseases/conditions that affect the gastrointestinal system,
             or functional gastrointestinal disorders. For screening the shortened screening
             version of the Bowel Disease Questionnaire (Appendix) will be used to exclude subjects
             with dyspepsia, irritable bowel syndrome or significant gastrointestinal symptoms. Of
             19 questions, participants have to have three or less positives to be eligible to
             participate.

          3. Unable to withdraw medications 48 hours prior to the study :

               -  Alter GI transit including laxatives, magnesium or aluminum-containing antacids,
                  prokinetics, erythromycin, narcotics, anticholinergics, tricyclic
                  antidepressants, selective serotonin re-uptake inhibitors (SSRIs) and newer
                  antidepressants.

               -  Analgesic drugs including opiates, nonsteroidal anti-inflammatory drugs (NSAIDs),
                  COX 2 inhibitors

               -  SSRI NOTE: Low stable doses of thyroid replacement, estrogen replacement, low
                  dose aspirin for cardioprotection and birth control pills or depot injections are
                  permissible.

          4. Female subjects who are pregnant or breast feeding.

          5. Clinical evidence (including physical exam, ECG, hemoglobin level and review of the
             medical history) of significant cardiovascular, respiratory, renal, hepatic,
             gastrointestinal, hematological, neurological, psychiatric, or other disease that
             interfere with the objectives of the study.

          6. Subjects who are considered by the investigator to be alcoholics not in remission or
             known substance abusers.

          7. Subjects who have participated in another clinical study within the past 30 days

          8. History of porphyria, renal (creatinine &gt; 1.5mg/dL) or significant liver impairment
             (transaminases, alkaline phosphatase of gamma-glutamyl transpeptidase (GGT) &gt;2 times
             upper limit of normal)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Camilleri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2011</study_first_submitted>
  <study_first_submitted_qc>December 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2011</study_first_posted>
  <results_first_submitted>November 8, 2012</results_first_submitted>
  <results_first_submitted_qc>December 13, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 17, 2012</results_first_posted>
  <last_update_submitted>December 13, 2012</last_update_submitted>
  <last_update_submitted_qc>December 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Michael Camilleri</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>tapentadol</keyword>
  <keyword>oxycodone</keyword>
  <keyword>mu-opiate</keyword>
  <keyword>stomach</keyword>
  <keyword>small intestine</keyword>
  <keyword>colon</keyword>
  <keyword>motility</keyword>
  <keyword>nausea</keyword>
  <keyword>constipation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tapentadol</title>
          <description>75 mg tapentadol tid</description>
        </group>
        <group group_id="P2">
          <title>Oxycodone</title>
          <description>5 mg oxycodone tid</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo tid</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tapentadol</title>
          <description>75 mg tapentadol tid</description>
        </group>
        <group group_id="B2">
          <title>Oxycodone</title>
          <description>5 mg oxycodone tid</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo tid</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="13"/>
            <count group_id="B4" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.99" spread="7.82"/>
                    <measurement group_id="B2" value="33.26" spread="12.94"/>
                    <measurement group_id="B3" value="39.48" spread="12"/>
                    <measurement group_id="B4" value="35.98" spread="11.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.27" spread="4.88"/>
                    <measurement group_id="B2" value="27.36" spread="6.11"/>
                    <measurement group_id="B3" value="25.16" spread="4.88"/>
                    <measurement group_id="B4" value="26.23" spread="5.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Colonic Transit, Geometric Center at 24 Hours</title>
        <description>The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol</title>
            <description>75 mg tapentadol tid</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone</title>
            <description>5 mg oxycodone tid</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tid</description>
          </group>
        </group_list>
        <measure>
          <title>Colonic Transit, Geometric Center at 24 Hours</title>
          <description>The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.06" spread="0.67"/>
                    <measurement group_id="O2" value="2.07" spread="0.6"/>
                    <measurement group_id="O3" value="2.17" spread="0.739"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Colonic Geometric Center at 8 and 48 Hours</title>
        <description>The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.</description>
        <time_frame>8 hours, 48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol</title>
            <description>75 mg tapentadol tid</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone</title>
            <description>5 mg oxycodone tid</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tid</description>
          </group>
        </group_list>
        <measure>
          <title>Colonic Geometric Center at 8 and 48 Hours</title>
          <description>The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Colonic geometric center at 8 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78" spread="0.589"/>
                    <measurement group_id="O2" value="0.75" spread="0.54"/>
                    <measurement group_id="O3" value="0.79" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colonic geometric center at 48 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.59" spread="1.16"/>
                    <measurement group_id="O2" value="3.51" spread="0.82"/>
                    <measurement group_id="O3" value="3.742" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Gastric Emptying Half-time (t1/2) at 24 Hours</title>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol</title>
            <description>75 mg tapentadol tid</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone</title>
            <description>5 mg oxycodone tid</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tid</description>
          </group>
        </group_list>
        <measure>
          <title>Gastric Emptying Half-time (t1/2) at 24 Hours</title>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159.2" spread="46.45"/>
                    <measurement group_id="O2" value="155.2" spread="38.44"/>
                    <measurement group_id="O3" value="124.7" spread="39.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Colonic Filling at 6 Hours</title>
        <description>Percent of the radio-labeled meal that reached the colon at 6 hours, indirectly reflecting small bowel transit time.</description>
        <time_frame>6 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol</title>
            <description>75 mg tapentadol tid</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone</title>
            <description>5 mg oxycodone tid</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tid</description>
          </group>
        </group_list>
        <measure>
          <title>Colonic Filling at 6 Hours</title>
          <description>Percent of the radio-labeled meal that reached the colon at 6 hours, indirectly reflecting small bowel transit time.</description>
          <units>percentage of radio-labeled meal</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.55" spread="32.3"/>
                    <measurement group_id="O2" value="38.6" spread="19.5"/>
                    <measurement group_id="O3" value="65.54" spread="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ascending Colon Emptying (AC t1/2)</title>
        <description>Ascending colon emptying t1/2 will be estimated by power exponential analysis of the proportionate emptying over time of counts from the colon. The primary data for this analysis will be the proportion of decay and depth-corrected counts in the ascending colon on the hourly scans on the first day of transit measurement and the 24 hour data.</description>
        <time_frame>Over the first 24 hours after ingestion of the radioisotopically labeled charcoal particles</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tapentadol</title>
            <description>75 mg tapentadol tid</description>
          </group>
          <group group_id="O2">
            <title>Oxycodone</title>
            <description>5 mg oxycodone tid</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tid</description>
          </group>
        </group_list>
        <measure>
          <title>Ascending Colon Emptying (AC t1/2)</title>
          <description>Ascending colon emptying t1/2 will be estimated by power exponential analysis of the proportionate emptying over time of counts from the colon. The primary data for this analysis will be the proportion of decay and depth-corrected counts in the ascending colon on the hourly scans on the first day of transit measurement and the 24 hour data.</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.92" spread="9.89"/>
                    <measurement group_id="O2" value="19.3" spread="6.27"/>
                    <measurement group_id="O3" value="17.88" spread="6.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were recorded during visits, and participants were contacted 5-7 days following the last dose of study medication to determine if any adverse events had occurred.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tapentadol</title>
          <description>75 mg tapentadol tid</description>
        </group>
        <group group_id="E2">
          <title>Oxycodone</title>
          <description>5 mg oxycodone tid</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo tid</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Light-headed</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Michael Camilleri</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-284-6218</phone>
      <email>camilleri.michael@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

